Literature DB >> 34107842

SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Katsuhisa Kurogi1,2, Mohammed I Rasool1,3, Fatemah A Alherz1,4, Amal A El Daibani1, Ahsan F Bairam1,5, Maryam S Abunnaja1, Shin Yasuda1,6, Lauren J Wilson1, Ying Hui1,7, Ming-Cheh Liu1.   

Abstract

INTRODUCTION: Cytosolic sulfotransferases (SULTs)-mediated sulfation is critically involved in the metabolism of key endogenous compounds, such as catecholamines and thyroid/steroid hormones, as well as a variety of drugs and other xenobiotics. Studies performed in the past three decades have yielded a good understanding about the enzymology of the SULTs and their structural biology, phylogenetic relationships, tissue/organ-specific/developmental expression, as well as the regulation of the SULT gene expression. An emerging area is related to the functional impact of the SULT genetic polymorphisms. AREAS COVERED: The current review aims to summarize our current knowledge about the above-mentioned aspects of the SULT research. An emphasis is on the information concerning the effects of the polymorphisms of the SULT genes on the functional activity of the SULT allozymes and the associated physiological, pharmacological, and clinical implications. EXPERT OPINION: Elucidation of how SULT SNPs may influence the drug-sulfating activity of SULT allozymes will help understand the differential drug metabolism and eventually aid in formulating personalized drug regimens. Moreover, the information concerning the differential sulfating activities of SULT allozymes toward endogenous compounds may allow for the development of strategies for mitigating anomalies in the metabolism of these endogenous compounds in individuals with certain SULT genotypes.

Entities:  

Keywords:  Cytosolic sulfotransferase; SNP; SULT; single-nucleotide polymorphism; sulfation

Mesh:

Substances:

Year:  2021        PMID: 34107842      PMCID: PMC8369464          DOI: 10.1080/17425255.2021.1940952

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.936


  218 in total

1.  Sulfating-activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 ((213)Arg) and ST1A3*2 ((213)His), both of which exist in Japanese as well as Caucasians.

Authors:  S Ozawa; M Shimizu; T Katoh; A Miyajima; Y Ohno; Y Matsumoto; M Fukuoka; Y M Tang; N P Lang; F F Kadlubar
Journal:  J Biochem       Date:  1999-08       Impact factor: 3.387

2.  Sulfation of chlorotyrosine and nitrotyrosine by human lung endothelial and epithelial cells: role of the human SULT1A3.

Authors:  Shin Yasuda; Tomoko Yasuda; Ming-Yih Liu; Sreerama Shetty; Steven Idell; Vijayakumar Boggaram; Masahito Suiko; Yoichi Sakakibara; Jian Fu; Ming-Cheh Liu
Journal:  Toxicol Appl Pharmacol       Date:  2010-12-17       Impact factor: 4.219

3.  Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis.

Authors:  Yunfei Wang; Margaret R Spitz; Amy Meng-Hsuan Tsou; Kerang Zhang; Nimisha Makan; Xifeng Wu
Journal:  Lung Cancer       Date:  2002-02       Impact factor: 5.705

4.  SULT1E1 genetic polymorphisms modified the association between phytoestrogen consumption and bone mineral density in healthy Korean women.

Authors:  S A Lee; J Y Choi; C S Shin; Y-C Hong; H Chung; D Kang
Journal:  Calcif Tissue Int       Date:  2006-09-11       Impact factor: 4.333

5.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Authors:  J S Montaner; P Reiss; D Cooper; S Vella; M Harris; B Conway; M A Wainberg; D Smith; P Robinson; D Hall; M Myers; J M Lange
Journal:  JAMA       Date:  1998-03-25       Impact factor: 56.272

6.  Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.

Authors:  Ji-Yeob Choi; Kyoung-Mu Lee; Sue Kyung Park; Dong-Young Noh; Sei-Hyun Ahn; Hye-Won Chung; Wonshik Han; Jeong Soo Kim; Sang Goo Shin; In-Jin Jang; Keun-Young Yoo; Ari Hirvonen; Daehee Kang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

7.  SULT1C3, an orphan sequence of the human genome, encodes an enzyme activating various promutagens.

Authors:  Walter Meinl; Claudia Donath; Heiko Schneider; Yasmin Sommer; Hansruedi Glatt
Journal:  Food Chem Toxicol       Date:  2007-09-06       Impact factor: 6.023

8.  Molecular cloning, expression, and functional characterization of a novel zebrafish cytosolic sulfotransferase.

Authors:  Takuya Sugahara; Chau Ching Liu; T Govind Pai; Ming Cheh Liu
Journal:  Biochem Biophys Res Commun       Date:  2003-01-17       Impact factor: 3.575

9.  SULT1A1 Arg213His polymorphism is associated with bladder cancer risk: a meta-analysis.

Authors:  Wencheng Li; Min Gu
Journal:  Med Sci Monit       Date:  2014-09-07

10.  Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Authors:  Hiromichi Matsuoka; Junji Tsurutani; Yasutaka Chiba; Yoshihiko Fujita; Masato Terashima; Takeshi Yoshida; Kiyohiro Sakai; Yoichi Otake; Atsuko Koyama; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  BMC Cancer       Date:  2017-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.